Published in Clin Cancer Res on April 01, 2002
Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78
DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med (2010) 1.32
DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol (2012) 1.19
Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF. J Natl Cancer Inst (2012) 1.07
Therapeutic targets in the ARF tumor suppressor pathway. Curr Med Chem (2007) 1.03
Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. World J Gastrointest Oncol (2014) 0.96
Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas. Br J Cancer (2008) 0.95
DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark Insights (2008) 0.95
Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer. Arch Med Sci (2011) 0.94
Epigenetics in bladder cancer. Int J Clin Oncol (2008) 0.84
Promoter hypermethylation of tumor suppressor genes correlates with tumor grade and invasiveness in patients with urothelial bladder cancer. Springerplus (2014) 0.81
An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget (2014) 0.80
The elements of human cyclin D1 promoter and regulation involved. Clin Epigenetics (2011) 0.79
Circulating Biomarkers in Bladder Cancer. Bladder Cancer (2016) 0.77
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer? Investig Clin Urol (2016) 0.76
Dynamics of ARF regulation that control senescence and cancer. BMB Rep (2016) 0.75
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
Drought sensitivity of the Amazon rainforest. Science (2009) 7.27
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
Profiling essential genes in human mammary cells by multiplex RNAi screening. Science (2008) 4.51
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol (2007) 3.88
A micrococcal nuclease homologue in RNAi effector complexes. Nature (2003) 3.67
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res (2011) 3.15
EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev (2011) 2.63
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2004) 2.54
Control of flowering and storage organ formation in potato by FLOWERING LOCUS T. Nature (2011) 2.32
Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell (2012) 2.18
Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene (2002) 2.09
E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. Hum Mol Genet (2005) 1.95
The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. Int J Cancer (2006) 1.91
DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol (2005) 1.88
Drought-mortality relationships for tropical forests. New Phytol (2010) 1.82
Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer (2004) 1.82
Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell (2009) 1.77
Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer (2008) 1.75
Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res (2008) 1.62
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood (2006) 1.57
Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancer. Ann Surg Oncol (2003) 1.45
The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res (2003) 1.43
Ultrasound measurement of gallbladder wall thickening as a diagnostic test and prognostic indicator for severe dengue in pediatric patients. Pediatr Infect Dis J (2007) 1.42
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One (2009) 1.36
Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA (2008) 1.35
Polycomb subunits Ezh1 and Ezh2 regulate the Merkel cell differentiation program in skin stem cells. EMBO J (2013) 1.33
PLCG1 mutations in cutaneous T-cell lymphomas. Blood (2014) 1.30
Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res (2006) 1.23
Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res (2013) 1.17
Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene (2002) 1.15
Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci (2013) 1.14
KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum Mol Genet (2011) 1.10
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol (2007) 1.09
Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett (2008) 1.09
Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res (2002) 1.08
Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res (2013) 1.07
TWIST1 is expressed in colorectal carcinomas and predicts patient survival. PLoS One (2011) 1.06
Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J Pathol (2003) 1.05
Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res (2003) 1.04
Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol (2002) 1.04
RNA interference: a promising approach to antiviral therapy? Trends Mol Med (2002) 1.02
p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer (2008) 1.01
An in vivo RNAi screening approach to identify host determinants of virus replication. Cell Host Microbe (2013) 1.01
Activity of trabectidin in desmoplastic small round cell tumor. Med Oncol (2010) 1.00
The miR-424(322)/503 cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes Dev (2014) 0.98
m.6267G>A: a recurrent mutation in the human mitochondrial DNA that reduces cytochrome c oxidase activity and is associated with tumors. Hum Mutat (2006) 0.97
Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med (2013) 0.97
Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res (2012) 0.95
Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. J Thorac Oncol (2008) 0.95
Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev (2011) 0.93
Protumorigenic effects of Snail-expression fibroblasts on colon cancer cells. Int J Cancer (2013) 0.93
Free energy lights the path toward more effective RNAi. Nat Genet (2003) 0.91
New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis (2011) 0.91
Extracellular tumor DNA in plasma and overall survival in breast cancer patients. Genes Chromosomes Cancer (2006) 0.89
Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer (2014) 0.89
Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res (2011) 0.88
Pooled shRNA screenings: experimental approach. Methods Mol Biol (2013) 0.88
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs (2010) 0.88
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol (2010) 0.88
Tumor-derived exosomes are enriched in ΔNp73, which promotes oncogenic potential in acceptor cells and correlates with patient survival. Hum Mol Genet (2013) 0.88
Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol (2003) 0.88
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin Cancer Res (2006) 0.86
A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer (2008) 0.86
The GADD45, ZBRK1 and BRCA1 pathway: quantitative analysis of mRNA expression in colon carcinomas. J Pathol (2005) 0.85
CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response. Oncotarget (2014) 0.85
Retention of transporter activities in cryopreserved, isolated rat hepatocytes. Drug Metab Dispos (2003) 0.84
Altered expression of the ZBRK1 gene in human breast carcinomas. J Pathol (2004) 0.84
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol (2013) 0.83